Shinichiro (Shin) Fuse, Ph.D.Partner at MPM Capital
Dr. Shinichiro (Shin) Fuse is focused on advancing MPM’s investment identification, due diligence and business development activities. He is also an investment committee member of MPM’s oncology-only crossover investment strategy (both public and private equities). Additionally, Shin supports MPM’s relationship with Astellas and is a board observer for CODA Biotherapeutics and Repare Therapeutics.
Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing, including partnerships with Five Prime Therapeutics, National Cancer Institute, Seattle Children’s Research Institute, and the acquisition of Pregenen. Previously, he was an Engagement Manager at Campbell Alliance (Syneos Health), where he worked with clients in the life science industry to support business development strategies and new product launches. Prior to joining Campbell Alliance, he was an Associate at PureTech Ventures, where he focused on venture creation activities in the microbiome space (Vedanta Biosciences) and technology due diligence. He also serves as a columnist and contributing writer for Nikkei Biotech, the leading journal covering the biotech industry in Japan.
Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.